Most MedTech startups begin with the same plan: hire a regulatory consultant, establish a quality management system (QMS), and obtain CE marking or FDA clearance or approval, depending on the pathway. While that approach is directionally correct, it represents only a fraction of the actual requirements.
What many R&D managers and startup CEOs realize too late: medical device consulting is not a uniform category. The term encompasses three fundamentally different disciplines. Choosing the right partner for the specific problem is relevant both for costs and for submission-ready evidence.
This guide provides a structured overview of the full landscape: what medical device consulting services actually cover, where technical development support transitions into regulatory strategy and where a preclinical contract research organization (CRO) comes into play.
The three categories in the medical device consulting market and why the distinction matters
When manufacturers and project managers search for “medical device consulting,” they are often looking for three entirely different things at the same time. The market rarely makes this clear. The following framework provides clarity.
1. Technical Consulting / Development Consulting
This is the engineering- and design-oriented discipline. Development consultants support the development and verification of your medical device: CAD modeling, FEM analysis, Design FMEA (Failure Mode and Effects Analysis), verification and validation planning (V&V planning), and prototype evaluation. Their primary deliverable is a technically verified design, documented in the development records (e.g., Design and Development File, DDF), in accordance with the requirements of ISO 13485, clause 7.3.10.
Note on terminology: With the introduction of the FDA Quality Management System Regulation (QMSR) in February 2026 and the increased alignment with ISO 13485, the terminology is shifting in part toward Design and Development File (DDF), while the term Design History File (DHF) remains relevant in the regulatory context.
In addition, the Medical Device File (MDF) is required under ISO 13485, clause 4.2.3.
It is important to note that the work of the development consultant does not end with the completion of the design phase (Design Freeze). Under the QMSR, technical consulting extends through to process validation (Design Transfer). According to MDR Annex II, Section 6.1, bench testing, software validation, and mechanical verification tests may be part of the preclinical data set, depending on the product and risk profile. The contract research organization (CRO) supplements this with biological and clinically relevant preclinical evidence: in vivo studies, biocompatibility assessment according to ISO 10993, histopathology.
2. Consulting for Medical Devices (Regulatory Affairs / QMS)
This is what most people mean when they search for “medical device consulting services.” Regulatory consultants guide you through the relevant compliance and submission pathways: MDR gap analyses, quality management system (QMS) development and certification to ISO 13485, preparation of technical documentation, clinical evaluation reports, PMCF strategies, and communication with the Notified Body.
A modern regulatory consultant does not limit themselves to setting up the quality management system (QMS). They must connect regulatory planning with the broader clinical strategy: the MDR requires continuous clinical evaluation, which is typically managed through documents such as the Clinical Evaluation Plan (CEP) and the Clinical Development Plan (CDP). It is crucial that the regulatory consultant helps to define clinically and regulatorily relevant endpoints of preclinical studies in a way that can support robust evidence generation for the clinical evaluation.
3. Preclinical Contract Research Organization (CRO): the operational evidence partner
A preclinical contract research organization is neither a regulatory consultant nor a development firm. This operational partner is responsible for generating preclinical evidence and implementing the study design operationally in close alignment with the regulatory strategy. This includes GLP-compliant or GLP-aligned studies where applicable, in vivo studies and biocompatibility testing (ISO 10993), as well as histopathological evaluations and traceable study reports.
Regulatory classification: Preclinical evidence (laboratory tests, animal studies, simulated use tests) is established in the EU MDR in Annex II, Section 6.1, not in Annex XIV.
Annex XIV governs the clinical evaluation and PMCF. The contract research organization provides primary data for Annex II; this data is integrated into the Clinical Evaluation Report (CER) as part of the clinical evaluation (Annex XIV), which is a component of the technical documentation pursuant to Annex II, Section 6.1(c).
Three-way comparison: Consulting partners for medical devices at a glance
| 01 |
Technical Consulting
Core Focus
Engineering, Design, Verification, Prototypes
Typical Services
CAD/FEM, Design FMEA, V&V planning, DDF/MDF, and design transfer
Role in the regulatory process
Translates product requirements into verifiable design and technical evidence.
Typical entry point
Concept phase through design transfer or process validation
Primary target group
R&D Directors, Engineering Leads, CTOs, and Development Engineers
Typical outcome
Verifiable product design, technical evidence, and transferable development documentation. |
| 02 |
MDR Consulting (Regulatory / QMS)
Core Focus
MDR, QMS, regulatory strategy, compliance, and lifecycle
Typical Services
MDR gap analysis, QMS implementation, technical documentation, Clinical Evaluation Plan / Development Plan (CEP/CDP), PMCF, and Notified Body support
Role in the regulatory process
Defines regulatory strategy, documentation structure, and compliance pathway.
Typical entry point
Early planning phase through regulatory submission
Primary target group
RA/QA Managers, startup CEOs, and project managers
Typical outcome
Regulatory strategy, robust documentation structure, and a traceable compliance pathway. |
| 03 |
Preclinical CRO
Core Focus
Study design, in vivo, biocompatibility, histology, and GLP report
Typical Services
GLP study planning, animal studies, biocompatibility testing, and histopathology
Role in the regulatory process
Generates preclinical evidence for the technical documentation and clinical evaluation.
Typical entry point
After determining the regulatory pathway, prior to first human use
Primary target group
R&D managers, project managers, and RA/QA managers during study planning
Typical outcome
Study reports, preclinical evidence, and usable data for technical documentation and clinical evaluation. |
CAD – Computer-Aided Design, FEM – Finite Element Method, FMEA – Failure Mode and Effects Analysis, V&V – Verification and Validation, DDF – Design and Development File, MDF – Medical Device File, MDR – Medical Device Regulation, QMS – Quality Management System, CEP – Clinical Evaluation Plan, CDP – Clinical Development Plan, PMCF – Post-Market Clinical Follow-up, GLP – Good Laboratory Practice, ISO – International Organization for Standardization, RA – Regulatory Affairs, QA – Quality Assurance, CTO – Chief Technology Officer, CEO – Chief Executive Officer
When do you need which partner? Four criteria for making the right decision
The right combination of partners depends on your project phase, the device category, and your target market. Use these four criteria to assess your current situation.
Criterion 1: Project Phase
Development consultants are particularly valuable during concept development through to the design freeze and beyond: under the QMSR, their scope extends to process validation (design transfer) and handover to the Medical Device File (MDF). Regulatory consultants should be involved early on, ideally as early as the product concept phase. A preclinical CRO is typically brought in as soon as the regulatory pathway is defined—often as early as the initial planning phase.
Criterion 2: Regulatory Function – Strategy vs. Evidence
The regulatory strategy defines the goal; preclinical evidence provides the proof. Your regulatory affairs consultant answers the question of what the regulatory authority needs to see. Your CRO, in addition, provides the data that substantiates this: GLP study reports, biocompatibility assessment, in vivo performance data, histology packages.
Criterion 3: Results and Deliverables
Development consulting provides the verified prototype as well as the Design and Development File (DDF) and, following design transfer, the Medical Device File (MDF). Regulatory consulting provides technical documentation, the Clinical Evaluation Plan (CEP) or Clinical Development Plan (CDP), or a 510(k)/PMA dossier structure. A preclinical contract research organization provides GLP-compliant study reports in accordance with MDR Annex II, Section 6.1, which the consultant compiles into the Clinical Evaluation Report (CER) in accordance with Annex XIV. The Clinical Evaluation Report (CER) is part of the technical documentation in accordance with Annex II, Section 6.1(c).
Criterion 4: Verification/Validation Planning (V&V Planning), Prototype Evaluation, and Design Verification
“Prototype evaluation consulting” is not a term defined by regulations. The correct regulatory framework is verification/validation planning (V&V planning) using design control. Design verification ensures that the product meets the technical specifications (design inputs). Design validation confirms that the product meets user requirements. As soon as the V&V planning requires in vivo evidence, the CRO becomes operationally involved and translates requirements from design verification into study-ready protocols in accordance with MDR Annex II, Section 6.1, as well as FDA 510(k) and PMA requirements.
Quick Checklist: Which Partner Do You Need?
Use this table to identify which consulting category applies to your current project situation.
| Partner Type | You need this partner if … |
|---|---|
| Development consulting |
|
| Regulatory / MDR consulting |
|
| Preclinical CRO |
|
Frequently Asked Questions About Medical Device Consulting
What is the difference between a medical device consultant and a CRO?
A medical device consultant advises on regulatory strategy, quality management systems (QMS), and compliance pathways, including the Clinical Evaluation Plan (CEP) and Clinical Development Plan (CDP). A contract research organization (CRO) conducts the studies that generate the safety and performance data for your regulatory submission. Consultants define what evidence you need. CROs generate that evidence.
When should I engage a preclinical CRO?
Ideally, as soon as your regulatory pathway is confirmed and before design freeze, where feasible. Early involvement allows the study design to optimize design decisions, such as material selection based on biocompatibility data.
What preclinical evidence is required for MDR Class IIb or III products?
According to EU MDR 2017/745, Annex II, Section 6.1, results from laboratory tests, simulated use, and, if applicable, animal studies are expected, depending on the product and risk profile. This data is incorporated as preclinical evidence into the Clinical Evaluation Report (CER), which meets the requirements of Annex XIV. The exact scope is defined by the Clinical Evaluation Plan (CEP) and the Clinical Development Plan (CDP).
What is meant by “prototype evaluation” in the context of verification/validation planning (V&V planning), and what role does the CRO play in this?
In the regulatory world of medical technology, there is no standard term for “prototype evaluation consulting.” The correct framework is verification and validation planning (V&V planning) using design control. Design verification ensures that the product meets the technical specifications (design inputs). Design validation confirms that the product meets user requirements.
Do I need all three types of partners for every medical device project?
In practice, many Class IIb and III programs in the EU or the U.S. require the involvement of all three partner types. Simpler Class I or IIa products may not require formal CRO engagement, depending on risk classification and the clinical evaluation pathway. If you are unsure, a consultation is the quickest way to gain clarity.
Next step: Clarify your evidence strategy in 30 minutes
→ Clarify your evidence strategy now
In a 30-minute consultation, we’ll clarify which preclinical studies your project needs—and in what order. No unnecessary regulatory jargon. Just a concrete, actionable evidence roadmap.
Sources & further links
External references
- FDA – 21 CFR Part 58 (Good Laboratory Practice for Nonclinical Laboratory Studies)
- EU MDR 2017/745
- ISO 13485:2016 – Medical devices — Quality management systems — Requirements for regulatory purposes
Internal links
- Choosing a Preclinical CRO: The next step after the consulting decision
- MedTech Consulting: CRO or consultant in the DACH context?
- Preclinical CRO Market Germany: Market overview for selecting the right partner
- ISO 13485 Consulting: The CRO as a QMS integration partner
- ISO 13485 Services: Which QMS services a CRO can provide
About the Author
Dr. rer. nat. Heiko Ziervogel is the founder and managing director of Medizin im Grünen. For more than two decades, he has supported preclinical study programs in medical device development, with a focus on translationally relevant in vivo models and robust preclinical evidence. His core areas include the planning and scientific supervision of preclinical studies as well as the development of traceable data strategies for different development and evaluation phases of medical devices. He supports MedTech companies in assessing preclinical questions along regulatory, technical, and translational requirements — including the early assessment of suitable alternatives and study-relevant reduction approaches.
Field of expertise: Preclinical in vivo studies · Preclinical evidence strategies · Medical device development · Translational study design